Indeed, GLP-1 agonists displayed an unexpected effectiveness in treating morbid obesity and its comorbidities [36], and seminal data showed a reduction in OSA symptoms burden and disease severity (expressed as AHI value) associated with GLP-1 receptor agonists [37,38,39]. The gene discussed is GLP1R; the disease is morbid obesity.